[Trovafloxacin].
Azanza
J R
JR
Servicio de Farmacología Clínica, Facultad de Medicina, Universidad de Navarra.
Ollero
D
D
Sádaba
B
B
García Quetglas
E
E
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000145:classification / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D016527:Drug Costs; D004341:Drug Evaluation; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects; D006089:Gram-Negative Anaerobic Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D015394:Molecular Structure; D009287:Naphthyridines / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C080163:trovafloxacin
Trovafloxacino.